How Do Viruses Avoid Inhibition by Endogenous Cellular MicroRNAs?

article has not abstract

Published in the journal: . PLoS Pathog 9(11): e32767. doi:10.1371/journal.ppat.1003694
Category: Pearls
doi: 10.1371/journal.ppat.1003694


article has not abstract


MicroRNAs (miRNAs) are an extensive family of small regulatory RNAs that function by binding to complementary mRNAs, primarily in the 3′ untranslated region (3′UTRs), and then inhibiting their expression by reducing mRNA translation and/or stability [1]. MiRNAs are initially transcribed as long pri-miRNAs, which are sequentially processed by the RNase III enzymes Drosha, in the nucleus, and Dicer, in the cytoplasm, to generate the mature, ∼22-nt miRNA [2]. This is then loaded into the RNA Induced Silencing Complex (RISC), which consists minimally of one of the four mammalian Argonaut proteins, Ago1 to Ago4, as well as a member of the GW182 protein family. MiRNAs function as guide RNAs to target RISC to complementary mRNA sequences on specific mRNA 3′UTRs. Analysis has revealed that complementarity to nucleotides 2 through 8 of the miRNA, the so-called seed region, is particularly important for effective RISC recruitment [1], although non-canonical sites, with incomplete seed complementarity, have also been reported [3]. Importantly, RISC recruitment to target sites that are occluded by RNA secondary structure or bound proteins is very inefficient [4].

Viruses and MicroRNAs

Upon infection of a cell, viruses encounter a wide range of miRNA species, generally more than 50 different miRNAs per cell, and these miRNAs vary greatly between tissues. For example, miR-122 is expressed at very high levels in hepatocytes, but is absent from almost all other cells, while miR-1 is primarily expressed in muscle tissue and miR-128 in neuronal cells [5][7]. Indeed, many of the more than 1000 known human miRNA species show a tissue-specific expression pattern [8], meaning that viruses that infect multiple cell types need a way to avoid inhibition by a wide range of miRNAs with distinct mRNA-targeting specificities.

Analyses of the interactions of viruses with cellular miRNAs have revealed that viruses can influence cellular miRNA biogenesis and effector mechanisms in several different ways. Viruses can clearly benefit from miRNA expression. For example, almost all herpesviruses that have been examined express substantial numbers of miRNAs, and these can facilitate viral replication and/or regulate viral entry or exit from latency [9]. While some DNA viruses also express miRNAs, including adeno and polyoma viruses, miRNAs have not been detected in any RNA viruses examined so far, with the exception of the retrovirus bovine leukemia virus (BLV), which transcribes short, pol III-driven miRNA precursors from integrated BLV proviruses [10]. Viruses can also benefit from cellular miRNA species, with the clearest example being Hepatitis C virus (HCV), which requires miR-122 for replication [5]. Moreover, several other viruses have been reported to induce specific cellular miRNAs, and it has been demonstrated that, in some instances, this induction facilitates viral replication in culture, apparently by down-regulating specific cellular mRNA targets with antiviral potential [11], [12].

While certain viruses can clearly benefit from cellular miRNAs, it has been unclear how viruses avoid inhibition of viral mRNA function by cellular miRNAs. Indeed, several reports demonstrating inhibition of viruses by cellular miRNAs have been published [13][15]. However, especially given that cellular miRNAs are highly conserved during evolution [1], it seems unlikely that viruses would fail to evolve mechanisms to prevent cellular miRNA-mediated inhibition in their normal target tissues. What these might be, however, is currently unclear. Several possible mechanisms can be proposed:

  • Viruses block miRNA function. This appears rare, as virus-infected cells generally contain normal levels of miRNAs, and most viruses can be inhibited by specific small interfering RNAs (siRNAs), which function indistinguishably from miRNAs in mammalian cells [16], or by insertion of target sites for endogenous cellular miRNAs into viral transcripts [17][20]. Indeed, the use of inserted cellular miRNA target sites as a way of inhibiting viral replication in tissues that express the cognate endogenous miRNA, while allowing unhindered viral replication in cells that lack this miRNA, has considerable potential in facilitating the development of novel attenuated viral vaccines or in targeting oncolytic viral vectors away from normal tissues [17][20]. Uniquely, in the case of poxviruses, it has been shown that miRNAs are degraded in infected cells [21]. In contrast, HIV-1 and influenza viruses, despite early reports to the contrary, have now been clearly shown to not block miRNA function [19], [22], and indeed, the tissue and/or species tropism of influenza virus can be readily manipulated by insertion of target sites for endogenous miRNAs [19].

  • Viruses evolve to avoid 3′UTR targets complementary to cellular miRNAs. Because full complementarity to the seed is generally critical for miRNA inhibition, single nucleotide mutations should block inhibition [1]. However, for viruses that can replicate in several different tissues, each expressing more than 50 distinct miRNAs, complete avoidance of all miRNAs may be very difficult to achieve. Nevertheless, especially for viruses that display a narrow tissue tropism, this mechanism seems very likely to be important.

  • Viruses evolve very short 3′UTRs. RISC recruitment to open reading frames (ORFs) does not effectively inhibit mRNA function, most probably because translating ribosomes sweep bound RISCs off the mRNA [1]. Therefore, mRNAs with very short 3′UTRs would be expected to be relatively refractory to miRNA-mediated inhibition. In fact, many RNA viruses express mRNAs bearing short 3′UTRs, and the short 3′UTRs that are present are often highly structured, which is predicted to also inhibit RISC binding [4]. RNA virus families that appear likely to use this strategy to avoid inhibition by endogenous cellular miRNAs include flaviviruses, picornaviruses, rhabdoviruses, and reoviruses.

  • Viruses evolve structured 3′UTRs. Some viruses, especially retroviruses, alphaviruses, and coronaviruses, contain extensive 3′UTRs in at least some viral mRNA species. For example, the HIV-1 mRNA that encodes Gag and Gag-Pol has a 3′UTR that is several thousand nucleotides in length. Similarly, the coronavirus mRNA encoding the viral ORF1a and ORF1b proteins has a 3′UTR more than 10,000 nucleotides in length. How do these very long 3′UTRs avoid functioning as targets for multiple miRNAs? One possibility is that these 3′UTRs have evolved high levels of RNA secondary structure, which would be predicted to globally restrict binding by miRNA-programmed RISCs [4].

Relatively little is known about the secondary structure of viral RNAs, although some data suggest that high levels of secondary structure are a common feature [23]. One viral RNA that has been examined in detail is the HIV-1 RNA genome, which also functions as the mRNA for the viral Gag and Gag-Pol proteins. This RNA has been shown to fold into an extensive secondary structure with relatively few areas that are unfolded and hence, presumably, are available for RISC binding [24]. This prediction has been validated by a comprehensive analysis of the susceptibility of the HIV-1 genome to small interfering RNAs (siRNAs), which in mammalian cells function indistinguishably from miRNAs [16]. These researchers generated over 9,000 siRNAs specific for the HIV-1 genome by sliding the siRNA target along the viral genome by one-nucleotide increments [25]. Relatively few of these siRNAs were found to inhibit HIV-1 replication and gene expression effectively, and those that did were predicted to bind to the few regions of the viral RNA genome that, using biochemical approaches, were predicted to adopt an open, unfolded conformation [24], [25].

Recently, the ability of the HIV-1 genome to bind to endogenous cellular miRNAs in relevant target cells (CD4+ T cells) or in a non-physiological target cell (HeLa cells) has been examined using a technology called photo-activatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP). The PAR-CLIP technique involves pulsing cells with the highly photoactivatable uridine analog 4-thiouridine and then crosslinking endogenous RNAs to bound proteins by irradiation at 365 nm [26]. Crosslinked proteins, and the bound RNAs, are recovered by immunoprecipitation of RISC using an Ago2-specific monoclonal antibody and the binding site footprinted by RNase treatment. The RISC binding sites are then comprehensively identified by deep sequencing of these small RNAs to generate sequence clusters that can be aligned to endogenous miRNA species.

Analysis of RISC binding to the HIV-1 genome indeed identified several binding sites that were occupied by RISCs programmed by endogenous cellular miRNAs and some of these could be shown, by indicator assays, to confer a modest repression of mRNA function [27]. However, perhaps the more interesting finding was that viral mRNAs, despite contributing more than 10% of the total mRNA transcriptome in HIV-1 infected cells, in fact gave rise to only approximately 0.2% of all assignable RISC binding sites, with the remaining approximately 99.8% being contributed by cellular mRNAs. That is, viral mRNAs are, at a minimum, 50-fold less likely to bind RISC than are cellular mRNAs, consistent with the idea that HIV-1-encoded mRNAs, at least, have evolved to globally avoid cellular miRNAs by adopting RNA secondary structures that preclude RISC binding.

While a more complete understanding of the interaction of viruses with cellular miRNAs must await a more detailed dissection of the effect of endogenous miRNAs on a wide range of viral species, current data suggest that viruses have likely evolved a number of strategies to avoid inhibition by these ubiquitous cellular regulatory RNAs. Whether the perturbation of these avoidance strategies has the potential to lead to the development of reagents that are useful in disease prevention, such as novel forms of attenuated viral vaccines, remains to be determined.


1. BartelDP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.

2. CullenBR (2004) Transcription and processing of human microRNA precursors. Mol Cell 16: 861–865.

3. LoebGB, KhanAA, CannerD, HiattJB, ShendureJ, et al. (2012) Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell 48: 760–770.

4. AmeresSL, MartinezJ, SchroederR (2007) Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130: 101–112.

5. JoplingCL, YiM, LancasterAM, LemonSM, SarnowP (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309: 1577–1581.

6. KwonC, HanZ, OlsonEN, SrivastavaD (2005) MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci U S A 102: 18986–18991.

7. SkalskyRL, CullenBR (2011) Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE 6: e24248 doi: 10.1371/journal.pone.0024248

8. LandgrafP, RusuM, SheridanR, SewerA, IovinoN, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401–1414.

9. GrundhoffA, SullivanCS (2011) Virus-encoded microRNAs. Virology 411: 325–343.

10. KincaidRP, BurkeJM, SullivanCS (2012) RNA virus microRNA that mimics a B-cell oncomiR. Proc Natl Acad Sci U S A 109: 3077–3082.

11. LinnstaedtSD, GottweinE, SkalskyRL, LuftigMA, CullenBR (2010) Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 84: 11670–11678.

12. HoBC, YuSL, ChenJJ, ChangSY, YanBS, et al. (2011) Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E. Cell Host Microbe 9: 58–69.

13. LecellierCH, DunoyerP, ArarK, Lehmann-CheJ, EyquemS, et al. (2005) A cellular microRNA mediates antiviral defense in human cells. Science 308: 557–560.

14. ZhengZ, KeX, WangM, HeS, LiQ, et al. (2013) Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome. J Virol 87: 5645–5656.

15. OtsukaM, JingQ, GeorgelP, NewL, ChenJ, et al. (2007) Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity 27: 123–134.

16. ZengY, YiR, CullenBR (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A 100: 9779–9784.

17. YlösmäkiE, HakkarainenT, HemminkiA, VisakorpiT, AndinoR, et al. (2008) Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 82: 11009–11015.

18. KellyEJ, HadacEM, GreinerS, RussellSJ (2008) Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278–1283.

19. LangloisRA, AlbrechtRA, KimbleB, SuttonT, ShapiroJS, et al. (2013) MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat Biotechnol

20. BarnesD, KunitomiM, VignuzziM, SakselaK, AndinoR (2008) Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4: 239–248.

21. BackesS, ShapiroJS, SabinLR, PhamAM, ReyesI, et al. (2012) Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. Cell Host Microbe 12: 200–210.

22. SanghviVR, SteelLF (2011) A re-examination of global suppression of RNA interference by HIV-1. PLoS ONE 6: e17246 doi: 10.1371/journal.pone.0017246

23. DavisM, SaganSM, PezackiJP, EvansDJ, SimmondsP (2008) Bioinformatic and physical characterizations of genome-scale ordered RNA structure in mammalian RNA viruses. J Virol 82: 11824–11836.

24. WattsJM, DangKK, GorelickRJ, LeonardCW, BessJWJr, et al. (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 460: 711–716.

25. TanX, LuZJ, GaoG, XuQ, HuL, et al. (2012) Tiling genomes of pathogenic viruses identifies potent antiviral shRNAs and reveals a role for secondary structure in shRNA efficacy. Proc Natl Acad Sci U S A 109: 869–874.

26. HafnerM, LandthalerM, BurgerL, KhorshidM, HausserJ, et al. (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141: 129–141.

27. WhisnantAW, BogerdHP, FloresO, HoP, PowersJG, et al. (2013) In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. mBio 4: e00193.

Hygiena a epidemiologie Infekční lékařství Laboratoř

Článek vyšel v časopise

PLOS Pathogens

2013 Číslo 11

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Zvyšte si kvalifikaci online z pohodlí domova

Imunitní trombocytopenie (ITP) u dospělých pacientů
nový kurz
Autoři: prof. MUDr. Tomáš Kozák, Ph.D., MBA

Pěnová skleroterapie
Autoři: MUDr. Marek Šlais

White paper - jak vidíme optimální péči o zubní náhrady
Autoři: MUDr. Jindřich Charvát, CSc.

Hemofilie - série kurzů

Faktory ovlivňující léčbu levotyroxinem

Všechny kurzy
Kurzy Doporučená témata Časopisy
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se

VIRTUÁLNÍ ČEKÁRNA ČR Jste praktický lékař nebo pediatr? Zapojte se! Jste praktik nebo pediatr? Zapojte se!